NATIONAL CANCER INSTITUTE
cancer Biomedical Informatics Grid™ (caBIG™)
Cancer Genome Anatomy Project (CGAP)
Cancer Genome Anatomy Project SNP500Cancer Database
Cancer Therapy Evaluation Program (CTEP)
Children's Oncology Group (COG)
Core Genotyping Facility (CGF)
Division of Cancer Epidemiology and Genetics (DCEG)
Office of Cancer Genomics (OCG)
Strategic Partnering to Evaluate Cancer Signatures (SPECS) Program
The Cancer Genome Atlas (TCGA)
The cancer Biomedical Informatics Grid™, is a voluntary network or grid connecting individuals and institutions to enable the sharing of data and tools, creating a World Wide Web of cancer research. The goal is to speed the delivery of innovative approaches for the prevention and treatment of cancer. The infrastructure and tools created by caBIG also have broad utility outside the cancer community. caBIG is being developed under the leadership of the National Cancer Institute's Center for Bioinformatics.
To learn more about caBIG, visit https://cabig.nci.nih.gov.
The goal of the NCI's Cancer Genome Anatomy Project is to determine the gene expression profiles of normal, precancer, and cancer cells, leading eventually to improved detection, diagnosis, and treatment for the patient. By collaborating with scientists worldwide, CGAP seeks to increase its scientific expertise and expand its databases for the benefit of all cancer researchers.
To learn more about CGAP, visit http://cgap.nci.nih.gov.
The goal of the SNP500Cancer project is to resequence 102 reference samples to find known or newly discovered single nucleotide polymorphisms (SNPs) which are of immediate importance to molecular epidemiology studies in cancer. SNP500Cancer provides a central resource for sequence verification of SNPs.
To learn more about the Cancer Genome Anatomy Project SNP500Cancer Database, visit http://snp500cancer.nci.nih.gov.
The mission of the Cancer Therapy Evaluation Program is to improve the lives of cancer patients by finding better ways to treat, control, and cure cancer. CTEP accomplishes this mission by funding an extensive national program of cancer research and by sponsoring clinical trials to evaluate new anti-cancer agents, with a particular emphasis on translational research to elucidate molecular targets and mechanisms of drug effects.
To learn more about the Cancer Therapy Evaluation program, visit http://ctep.cancer.gov/index.html.
The Children's Oncology Group (COG) is supported by the National Cancer Institute to conduct clinical trials devoted exclusively to children and adolescents with cancer. COG. develops and coordinates cancer clinical trials conducted at its more than 200 member institutions, which include cancer centers of all major universities and teaching hospitals throughout the United States and Canada, as well as sites in Europe and Australia. Through the COG. network of member institutions, children with cancer, regardless of where they live, can access state-of-the art therapies and the collective expertise of world-renowned pediatric specialists.
In addition, COG researchers are evaluating potential risk factors for a variety of childhood cancers. Very large studies of the following cancers have been completed: childhood acute lymphoblastic leukemia, acute myeloid leukemia, non-Hodgkin lymphoma, primitive neuroectodermal tumors of the brain, astrocytoma, neuroblastoma, and germ cell tumors. COG has also established a Childhood Cancer Research Network that creates a national registry of children with cancer. This initiative builds upon the unique NCI-supported national clinical trials system for treating children with cancer.
To learn more about the Children's Oncology Group, visit http://www.childrensoncologygroup.org/
The goal of the Core Genotyping Facility is to meet the genotyping and DNA sequencing needs of the NCI's Division of Cancer Epidemiology and Genetics (DCEG) and Center for Cancer Research (CCR). The facility performs high-throughput genotyping and sequencing to support genetic analysis for a broad range of projects for the intramural research program of the NCI.
To learn more about CGF, visit http://cgf.nci.nih.gov/.
The Division of Cancer Epidemiology and Genetics is an intramural research program of the National Cancer Institute, National Institutes of Health, that conducts population and multidisciplinary research to discover the genetic and environmental determinants of cancer and new approaches to cancer prevention.
To learn more about DCEG, visit http://dceg.cancer.gov.
The mandate of Office of Cancer Genomics at the National Cancer Institute is to enhance understanding of the molecular mechanisms of cancer, with the ultimate goal of improving the prevention, early detection, diagnosis, and treatment of cancer.
To learn more about OCG, visit http://www3.cancer.gov/ocg.
The Strategic Partnering to Evaluate Cancer Signatures Program is a scientific program of the Cancer Diagnosis Program (CDP) of the National Cancer Institute, to establish strategic partnerships that bring together the interdisciplinary teams needed to evaluate the potential clinical utility of molecular signatures.
To learn more about the Strategic Partnering to Evaluate Cancer Signatures Program, visit http://www.cancerdiagnosis.nci.nih.gov/.
The Cancer Genome Atlas is a comprehensive and coordinated effort to accelerate our understanding of the molecular basis of cancer through the application of genome analysis technologies, including large-scale genome sequencing. TCGA is a joint effort of the National Cancer Institute (NCI) and the National Human Genome Research Institute (NHGRI), which are both part of the National Institutes of Health, U.S. Department of Health and Human Services.
To learn more about TCGA, visit http://cancergenome.nih.gov.
